Abstract:ImportanceRadioactive iodine (RAI) has been used extensively to treat hyperthyroidism since the 1940s. Although widely considered a safe and effective therapy, RAI has been associated with elevated risks of total and site-specific cancer death among patients with hyperthyroidism.ObjectiveTo determine whether greater organ- or tissue-absorbed doses from RAI treatment are associated with overall and site-specific cancer mortality in patients with hyperthyroidism.Design, Setting, and ParticipantsThis cohort study is a 24-year extension of the multicenter Cooperative Thyrotoxicosis Therapy Follow-up Study, which has followed up US and UK patients diagnosed and treated for hyperthyroidism for nearly 7 decades, beginning in 1946. Patients were traced using records from the National Death Index, Social Security Administration, and other resources. After exclusions, 18 805 patients who were treated with RAI and had no history of cancer at the time of the first treatment were eligible for the current analysis. Excess relative risks (ERRs) per 100-mGy dose to the organ or tissue were calculated using multivariable-adjusted linear dose-response models and were converted to relative risks (RR = 1 + ERR). The current analyses were conducted from April 28, 2017, to January 30, 2019.ExposuresMean total administered activity of sodium iodide I 131 was 375 MBq for patients with Graves disease and 653 MBq for patients with toxic nodular goiter. Mean organ or tissue dose estimates ranged from 20 to 99 mGy (colon or rectum, ovary, uterus, prostate, bladder, and brain/central nervous system), to 100 to 400 mGy (pancreas, kidney, liver, stomach, female breast, lung, oral mucosa, and marrow), to 1.6 Gy (esophagus), and to 130 Gy (thyroid gland).Main Outcomes and MeasuresSite-specific and all solid-cancer mortality.ResultsA total of 18 805 patients were included in the study cohort, and the mean (SD) entry age was 49 (14) years. Most patients were women (14 671 [78.0%]), and most had a Graves disease diagnosis (17 615 [93.7%]). Statistically significant positive associations were observed for all solid cancer mortality (n = 1984; RR at 100-mGy dose to the stomach = 1.06; 95% CI, 1.02-1.10;P = .002), including female breast cancer (n = 291; RR at 100-mGy dose to the breast = 1.12; 95% CI, 1.003-1.32;P = .04) and all other solid cancers combined (n = 1693; RR at 100-mGy dose to the stomach = 1.05; 95% CI, 1.01-1.10;P = .01). The 100-mGy dose to the stomach and breast corresponded to a mean (SD) administered activity of 243 (35) MBq and 266 (58) MBq in patients with Graves disease. For every 1000 patients with hyperthyroidism receiving typical doses to the stomach (150 to 250 mGy), an estimated lifetime excess of 19 (95% CI, 3-40) to 32 (95% CI, 5-66) solid cancer deaths could occur.Conclusions and RelevanceIn RAI-treated patients with hyperthyroidism, greater organ-absorbed doses appeared to be modestly positively associated with risk of death from solid cancer, including breast cancer. Additional studies are needed of the risks and advantages of all major treatment options available to patients with hyperthyroidism.

Long-term biological effects after acute 131I-administration of two rat models (with and without thyroid)

Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure

[The effect of long-term external ionizing radiation on the functional activity of rat thyroid under enhanced potassium iodide consumption]

[Functional and morphological characterization of rat thyroid gland at remote periods following single high and low dose radiation exposure]

Effect of radioactive iodine-induced hypothyroidism on longitudinal bone growth during puberty in immature female rats

Thyroid Radiation Doses During Radioimmunotherapy of CEA-expressing Tumours with 131I-Labelled Monoclonal Antibodies.

Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism

The effect of 131I on apoptosis of thyrocytes in patients with Graves disease

Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease

Metabolomics evaluation of repeated administration of potassium iodide on adult male rats

The Effect of Iodine Excess on Thyroid Stereology at Rats

[Late effects of ionizing radiations on the thyroid gland]

Clinical study of 431 cases with hyperthyroidism after radioiodine therapy

Experimental study on the relationship between different iodine intakes and their thyroid function in rats

Effect of Presence of Uni- or Bilateral Thyroid Adenoma on Recovery of Pituitary-Thyroid Axis and Creatinine Concentration in Radioiodine-Treated Cats

Evaluation of Serum Tumor Markers Variation, Following The Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

Morphological study on thyroid gland of rats with an excess of long term iodine intake

Influence of radioactive iodine therapy on liver function in patients with differentiated thyroid cancer

Effects of 131I therapy for differentiated thyroid carcinoma on liver and renal function

Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer.

Long-Term Outcomes of Radioiodine Therapy for Juvenile Graves Disease with Emphasis on Subsequently Detected Thyroid Nodules: A Single Institution Experience from Japan